MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

33.64 2.69

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

32.72

Maximum

33.94

Fő mutatók

By Trading Economics

Bevétel

7.7M

-41M

Értékesítés

3.5M

110M

Profit margin

-37.032

Munkavállalók

1,869

EBITDA

1.4M

-55M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+59.84% upside

Osztalékok

By Dow Jones

Következő eredményjelentés

2025. nov. 11.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-439M

3.8B

Előző nyitás

30.95

Előző zárás

33.64

Hangulat hírek alapján

By Acuity

100%

0%

361 / 371 Rangsor szerint Healthcare

Technikai pontszám

By Trading Central

Bizalom

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2025. okt. 7. 16:58 UTC

Eredményjelentés

BMW Trims 2025 View, Citing Weaker Performance in China

2025. okt. 7. 23:43 UTC

Piaci beszéd

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025. okt. 7. 23:36 UTC

Piaci beszéd

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025. okt. 7. 23:19 UTC

Piaci beszéd

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025. okt. 7. 22:50 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. okt. 7. 22:50 UTC

Piaci beszéd

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025. okt. 7. 22:40 UTC

Piaci beszéd

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025. okt. 7. 21:56 UTC

Piaci beszéd

Global Equities Roundup: Market Talk

2025. okt. 7. 21:56 UTC

Piaci beszéd

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025. okt. 7. 20:50 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. okt. 7. 20:44 UTC

Forró részvények

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025. okt. 7. 19:42 UTC

Piaci beszéd

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025. okt. 7. 19:23 UTC

Felvásárlások, összeolvadások, átvételek

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025. okt. 7. 19:07 UTC

Piaci beszéd

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025. okt. 7. 19:02 UTC

Piaci beszéd

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025. okt. 7. 16:20 UTC

Piaci beszéd

Tech, Media & Telecom Roundup: Market Talk

2025. okt. 7. 16:20 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. okt. 7. 16:20 UTC

Piaci beszéd

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025. okt. 7. 16:15 UTC

Piaci beszéd

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025. okt. 7. 16:15 UTC

Piaci beszéd

Global Commodities Roundup: Market Talk

2025. okt. 7. 15:37 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. okt. 7. 15:37 UTC

Piaci beszéd

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025. okt. 7. 15:33 UTC

Piaci beszéd

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025. okt. 7. 15:25 UTC

Piaci beszéd

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025. okt. 7. 15:15 UTC

Piaci beszéd

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025. okt. 7. 15:04 UTC

Piaci beszéd

Market Talk Roundup: Latest on U.S. Politics

2025. okt. 7. 15:04 UTC

Piaci beszéd

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025. okt. 7. 14:56 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. okt. 7. 14:56 UTC

Piaci beszéd

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025. okt. 7. 14:52 UTC

Eredményjelentés

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

59.84% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 52.57 USD  59.84%

Magas 69 USD

Alacsony 39 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

7 ratings

6

Vétel

1

Tartás

0

Eladás

Technikai pontszám

By Trading Central

28.13 / 31.12Támogatás & ellenállás

Rövid táv

Very Strong Bearish Evidence

Középtáv

Bearish Evidence

Hosszú táv

Bullish Evidence

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat